MENU

Fox Chase Cancer Center News

December 2, 2021

Two Fox Chase Cancer Center Researchers Join American Lung Association’s 2021-2022 Research Team and Receive a Total Research Investment of $200,000 to Improve Lung Health and Prevent Lung Disease

PHILADELPHIA (December 2, 2021) – As new and pressing lung health challenges emerge with the COVID-19 pandemic to climate change and youth e-cigarette use, researchers have been at the forefront of scientific breakthroughs. In Philadelphia, two distinguished scientists are being awarded research grants to help study how lung diseases, including COVID-19 and lung cancer, impact people’s lives.

December 2, 2021

Fox Chase Cancer Center, The Wistar Institute Announce Opening of Phase 1 Clinical Trial of Anticancer Drug Candidate

PHILADELPHIA (December 2, 2021)Fox Chase Cancer Center has opened an investigator-initiated, phase 1 clinical trial to evaluate the safety and efficacy of gamitrinib in patients with advanced cancer. Gamitrinib is a first-in-class, mitochondrial-targeted inhibitor of the molecular chaperone heat shock protein-90 (HSP90) that works by inhibiting tumor cell metabolism and survival.

December 1, 2021

Cihangir Duy Receives V Scholar Award to Study Role of DNA Methylation in ‘Dormant’ Leukemia Cells

PHILADELPHIA (December 1, 2021)—Cihangir Duy, PhD, MS, an assistant professor in the Cancer Signaling and Epigenetics Program at Fox Chase Cancer Center, has been awarded a two-year V Scholar Award of $200,000. This grant will fund research into how certain acute myeloid leukemia (AML) cells can reinitiate leukemia after chemotherapy.

November 30, 2021

Fox Chase Cancer Center’s Suzanne Miller Takes Lead for Special Edition of Translational Behavioral Medicine

PHILADELPHIA (November 30, 2021)—Suzanne M. Miller, PhD, a professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has spearheaded a recent special edition of Translational Behavioral Medicine published today that summarizes several major lines of cancer prevention and control research and outlines future directions.

November 24, 2021

Fox Chase Cancer Center Welcomes Pamela Handelsman

PHILADELPHIA (November 24, 2021)—Fox Chase Cancer Center is pleased to announce the hiring of Pamela Handelsman, PsyD, as an assistant professor in the Section of Psychiatry, where she will help patients cope with cancer across the entire care continuum, from initial diagnosis to end of life or survivorship.

November 22, 2021

Jaye Gardiner Receives Inaugural Black in Cancer Postdoctoral Fellowship for Her Pancreatic Cancer Research

PHILADELPHIA (November 22, 2021)—Jaye Gardiner, PhD, a postdoctoral researcher at Fox Chase Cancer Center, has received an inaugural Black in Cancer postdoctoral fellowship, which is funded by Emerald Foundation Inc. Gardiner will receive $75,000 annually for three years, money that will fund her research into pancreatic ductal adenocarcinoma (PDAC).  

November 22, 2021

AlphaFold System for Protein Structure Prediction Could Enhance Development of New Drugs

PHILADELPHIA (November 22, 2021)—Fox Chase Cancer Center has begun using a new artificial intelligence-powered system called AlphaFold, which allows researchers to develop accurate predictions of how proteins fold into their final structures, making it a tool that could enhance the development of new drugs.

November 18, 2021

Fox Chase Researchers Use Liquid Biopsies to Study Genetic Variants in Tumors for Potential Therapies in Breast Cancer

PHILADELPHIA (November 18, 2021)—In a recent study using liquid biopsies and tumor tissue biomarkers, researchers at Fox Chase Cancer Center found that PARP inhibitors and PD-1/PDL1 blocking immunotherapy could be considered an effective treatment in eligible inflammatory breast cancer patients.

Pages

Connect with Fox Chase